Literature DB >> 11036120

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

C J Packard1, D S O'Reilly, M J Caslake, A D McMahon, I Ford, J Cooney, C H Macphee, K E Suckling, M Krishna, F E Wilkinson, A Rumley, G D Lowe.   

Abstract

BACKGROUND: Chronic inflammation is believed to increase the risk of coronary events by making atherosclerotic plaques in coronary vessels prone to rupture. We examined blood constituents potentially affected by inflammation as predictors of risk in men with hypercholesterolemia who were enrolled in the West of Scotland Coronary Prevention Study, a trial that evaluated the value of pravastatin in the prevention of coronary events.
METHODS: A total of 580 men who had had a coronary event (nonfatal myocardial infarction, death from coronary heart disease, or a revascularization procedure) were each matched for age and smoking status with 2 control subjects (total, 1160) from the same cohort who had not had a coronary event. Lipoprotein-associated phospholipase A2, C-reactive protein, and fibrinogen levels, and the white-cell count were measured at base line, along with other traditional risk factors. The association of these variables with the risk of coronary events was tested in regression models and by dividing the range of values according to quintiles.
RESULTS: Levels of C-reactive protein, the white-cell count, and fibrinogen levels were strong predictors of the risk of coronary events; the risk in the highest quintile of the study cohort for each variable was approximately twice that in the lowest quintile. However, the association of these variables with risk was markedly attenuated when age, systolic blood pressure, and lipoprotein levels were included in multivariate models. Levels of lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase), the expression of which is regulated by mediators of inflammation, had a strong, positive association with risk that was not confounded by other factors. It was associated with almost a doubling of the risk in the highest quintile as compared with the lowest quintile.
CONCLUSIONS: Inflammatory markers are predictors of the risk of coronary events, but their predictive ability is attenuated by associations with other coronary risk factors. Elevated levels of lipoprotein-associated phospholipase A2 appear to be a strong risk factor for coronary heart disease, a finding that has implications for atherogenesis and the assessment of risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11036120     DOI: 10.1056/NEJM200010193431603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  170 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

Review 2.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 3.  Lesions and lipids and radicals--O my!

Authors:  James M Wilson; Brian Walton
Journal:  Tex Heart Inst J       Date:  2004

Review 4.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

5.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

6.  Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

Authors:  Benjamin Young; Kathleen E Squires; Lisa L Ross; Lizette Santiago; Louis M Sloan; Henry H Zhao; Brian C Wine; Gary E Pakes; David A Margolis; Mark S Shaefer
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-05       Impact factor: 2.205

7.  Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study.

Authors:  Anandita Agarwala; Salim Virani; David Couper; Lloyd Chambless; Eric Boerwinkle; Brad C Astor; Ron C Hoogeveen; Joe Coresh; A Richey Sharrett; Aaron R Folsom; Tom Mosley; Christie M Ballantyne; Vijay Nambi
Journal:  Atherosclerosis       Date:  2016-08-25       Impact factor: 5.162

Review 8.  The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Authors:  Salim S Virani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

9.  Vitamin C treatment reduces elevated C-reactive protein.

Authors:  Gladys Block; Christopher D Jensen; Tapashi B Dalvi; Edward P Norkus; Mark Hudes; Patricia B Crawford; Nina Holland; Ellen B Fung; Laurie Schumacher; Paul Harmatz
Journal:  Free Radic Biol Med       Date:  2008-10-10       Impact factor: 7.376

10.  Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.

Authors:  Koto Ishida; Brett Cucchiara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.